A panel of experts on multiple myeloma discuss the importance of GPRC5D as a target of interest in relapsed/refractory disease and discuss their experiences with talquetamab in clinical practice.
Video content above is prompted by the following:
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings
August 27th 2024Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.